Invenomic Capital Management Buys Stake in CONMED Corporation

The investment firm purchased over 420,000 shares of the medical device company in the third quarter.

Mar. 16, 2026 at 12:20pm

Got story updates? Submit your updates here. ›

Invenomic Capital Management LP, an investment management firm, purchased a new position in shares of CONMED Corporation (NYSE:CNMD) during the third quarter of 2025. The firm bought 420,003 shares of the company's stock, valued at approximately $19.75 million, making it a 1.36% owner of CONMED at the end of the reporting period.

Why it matters

This investment by Invenomic Capital Management represents a significant stake in CONMED, a leading manufacturer of medical devices for minimally invasive procedures. The purchase suggests Invenomic sees potential in CONMED's business and future growth prospects, which could signal positive sentiment about the company's performance and outlook among institutional investors.

The details

According to a 13F filing with the SEC, Invenomic Capital Management LP bought the 420,003 shares of CONMED in the third quarter of 2025. This new position makes Invenomic one of the larger institutional investors in the medical device company.

  • Invenomic Capital Management purchased the CONMED shares in the third quarter of 2025.

The players

Invenomic Capital Management LP

An investment management firm that purchased a new stake in CONMED Corporation.

CONMED Corporation

A global medical technology company that develops, manufactures, and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures.

Got photos? Submit your photos here. ›

The takeaway

Invenomic Capital Management's investment in CONMED suggests the firm sees strong potential in the medical device company's future performance and growth prospects. This could signal positive sentiment about CONMED among institutional investors.